This article is more than 5 years old. Information may no longer be current.

Laser platform for glaucoma, cataract treatment receives CE mark

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Optimis Fusion integrated laser platform from Quantel Medical has been granted a CE mark, according to a press release.

The system has the capability to perform both selective laser trabeculoplasty photoregeneration therapy and traditional YAG photodisruption treatments, the release said.

Quantel plans to begin commercialization in all CE mark-approved countries immediately. Meanwhile, U.S. Food and Drug Administration approval is expected this year, according to the release.